USPTO serial 98589952
DLVR-X
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- CLAYTON, CHERYL A
- Law office
- TMEG LAW OFFICE 102
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with DLVR-X?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alyssa M. Worsham
Alyssa M. Worsham Wilson Sonsini Goodrich & Rosati650 Page Mill RoadPalo Alto, CA 94304-1050United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | pharmaceutical preparations for gene therapy and gene editing; drug delivery agents that facilitate de livery of pharmaceuticals, namely, drug delivery agents consisting of particles that facilitate delivery of a wide range of pharmaceuticals; drug carriers for medical use, namely, drug delivery agents in the form of engineered particles that facilitate the delivery of pharmaceutical preparations for delivering drugs to human cells, tissues and organs; cell and gene therapy products for increasing protein expression in cells namely, engineered particles; pharmaceutical and biological preparations for delivering agents including proteins, nucleic acids, ribonucleoproteins, and small molecules into cells for the prevention, diagnosis and treatment of genetic diseases, namely, cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes; pharmaceutical and biological preparations for delivering therapeutic agents including proteins, nucleic acids, ribonucleoproteins, and small molecules for treatment of cancer, including hematological and solid tumors, autoimmune diseases, cardiovascular disease, respiratory disease, pulmonary disease, central nervous system diseases and disorders, mitochondrial diseases and disorders, endocrine disorders, gastrointestinal diseases, genetic diseases and disorders, auditory processing disorders (APD) and hearing loss disorders, inflammatory diseases, acquired and innate immunodeficiencies, kidney disease, liver disease, metabolic diseases and disorders, musculoskeletal disorders, neurodegenerative diseases and disorders, neurological diseases and disorders, brain disorders and diseases, neuromuscular and viral diseases and disorders, blood disorders, bone growth disorders, skin disorders, arthritis, hypertension, pain, stroke, obesity and diabetes | ACTIVE | — |
| 010 | drug delivery agents that facilitate delivery of pharmaceuticals, namely, engineered particles | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 4, 2025 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Aug 4, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 15, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Apr 15, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jan 20, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 20, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 20, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Dec 21, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 20, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jun 7, 2024 | NWAP | NEW APPLICATION ENTERED | — |